

# Momelotinib During and After HCT in Myelofibrosis

NCT07104799

---

<b>Status</b>	RECRUITING
<b>Phase</b>	Phase 1
<b>Sponsor</b>	Massachusetts General Hospital
<b>Enrollment</b>	28 participants

## Key Eligibility Criteria

---

### Inclusion (17)

- Participants must have pathologically confirmed primary myelofibrosis (PMF) according to WHO criteria or secondary myelofibrosis as defined by the IWG-MRT criteria.
  - Intermediate-2/ high-risk disease as per Dynamic IPSS (DIPSS) Plus criteria OR
  - Intermediate-1 risk disease with at least one of the following unfavorable features known to impact the survival adversely
  - Red cell transfusion dependency
  - Unfavorable Karyotype
- ... and 12 more (see full listing online)

### Exclusion (32)

- \- Ability to understand and the willingness to sign a written informed consent document.
  - Known intolerance or hypersensitivity to any JAK inhibitor, including ruxolitinib, fedratinib, pacritinib, momelotinib or any other JAK inhibitor, its metabolites or formulation excipients.
  - Has had any major surgery within 28 days prior to randomization
  - Has received treatment with an investigational agent within 4 weeks of the first dose of study intervention
  - Has received immunosuppressive agents within 28 days
- ... and 27 more (see full listing online)

## Locations (1 total)

---

Massachusetts General Hospital, Boston, Massachusetts, United States